BeOne Medicines Raises 2026 Revenue Guidance to $6.9B-$7.0B and Announces Tacabrutide Filing Timeline
BeOne Medicines AG reported strong third-quarter performance, highlighted by total sales of $1.4 billion, representing a 34% increase year-over-year. Following these results, the company raised its revenue outlook for 2026 to a range of $6.9 billion to $7.0 billion. Looking ahead to its product pipeline, management announced plans to file for tacabrutide in mid-2027. CEO and Co-Founder John Oyler noted that the company is currently executing at its highest historical level, driven by significant growth in U.S. sales.
Tickers: $ONC